# Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

> **NCT03319901** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 82 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Standard Chemotherapy

## Key facts

- **NCT ID:** NCT03319901
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-10-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03319901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03319901, "Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03319901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*